Wegovy Linked to Improved Liver Markers in MASH Patients with Lower BMI

A new post hoc analysis presented at The Liver Meeting® 2026 revealed that Wegovy (semaglutide 2.4 mg) was associated with improved liver markers in adults with metabolic dysfunction-associated steatohepatitis (MASH) who also had liver scarring and a BMI under 27 kg/m². This data expands understanding of semaglutide's potential benefits for a broader MASH patient population, including those with lower BMIs.